A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling

3

4 Jason A. Hackney^{#1}, Haridha Shivram^{#1}, Jason Vander Heiden¹, Chris Overall¹, Luz Orozco¹, Xia 5 Gao¹, Nathan West, Aditi Qamra², Diana Chang¹, Arindam Chakrabarti¹, David F. Choy¹, Alexis 6 J. Combes³, Tristan Courau³, Gabriela K. Fragiadakis³, Arjun Arkal Rao³, Arja Ray³, Jessica Tsui³, 7 Kenneth Hu³, Nicholas F. Kuhn³, Matthew F. Krummel³, David J. Erle³, Kirsten Kangelaris³, 8 Aartik Sarma³, Zoe Lyon³, Carolyn S. Calfee³, Prescott G. Woodruff³, Rajani Ghale³, Eran Mick³, 9 Ashley Byrne³, Beth Shoshana Zha³, Charles Langelier³, Carolyn M. Hendrickson³, Monique G.P. 10 van der Wijst⁴, George C. Hartoularos³, Tianna Grant³, Raymund Bueno³, David S. Lee³, John R. 11 Greenland³, Yang Sun³, Richard Perez³, Anton Ogorodnikov³, Alyssa Ward³, Chun Jimmie Ye³, 12 UCSF COMET Consortium³, Thiru Ramalingam¹, Jacqueline M. McBride¹, Fang Cai¹, Anastasia 13 Teterina², Min Bao¹, Larry Tsai¹, Ivan O. Rosas⁵, Aviv Regev¹, Sharookh B. Kapadia¹, Rebecca

- ¹⁴ N. Bauer¹, Carrie M. Rosenberger^{1*}
- 15
- ¹⁶ 1. Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.
- ¹⁷ 2. Hoffman-La Roche Limited. 7070 Mississauga Road. Mississauga, ON L5N 5M8 Canada
- ¹⁸ 3. University of California San Francisco, San Francisco, CA, USA.
- ¹⁹ 4. Department of Genetics, University of Groningen, University Medical Center Groningen,
 ²⁰ Groningen, The Netherlands.
- ²¹ 5. Baylor College of Medicine, 7200 Cambridge St, Houston, TX 77030, USA
- ²² [#]J.A. Hackney and H. Shivram are co-first authors.
- ²⁴ *Corresponding author: Carrie M Rosenberger, <u>Rosenberger.carrie@gene.com</u>, 1-650-467-9065
- Additional UCSF COMET Consortium authors are listed in the acknowledgements
- ²⁸ Word count: 10 526, abstract: 200 words
- ²⁹ Tables/Figures: 7 Figures, 1 Table, 7 supplemental Figures, 1 supplemental Table

³¹ Conflict of Interest Statement

32 J.A.H., H.S., J.V.H., C.O., L.O., X.G., N.W., A.Q., D.C., A.C, D.F.C., T.R, J.M.M., F.C., A.T., M.B., L.T., 33 A.R., S.B.K., R.N.B., and C.M.R. were employees of Genentech, Inc. at the time of this study and own 34 equity in Roche. The COMET study was supported in part by Genentech funding. C.J.Y. is a Scientific 35 Advisory Board member for and holds equity in Related Sciences and ImmunAI, a consultant for and holds 36 equity in Maze Therapeutics, and a consultant for TReX Bio. C.J.Y. has received research support from 37 Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, and Genentech. C.S.C. has received research funding 38 from Roche-Genentech for an unrelated project as well as from NIH, DOD, and Quantum Leap Healthcare 39 Collaborative. C.S.C. is a consultant for Vasomune, Quark, and Gen1e Life Sciences. C.H. is a consultant 40 for Spring Discovery but does not have any financial interest in the company nor is the work related to what 41 is covered in this manuscript. AR is a co-founder and equity holder of Celsius Therapeutics, an equity 42 holder in Immunitas Therapeutics and, until 31 July 2020, was a scientific advisory board member of 43 ThermoFisher Scientific, Syros Pharmaceuticals, Asimov and Neogene Therapeutics. AR is a named 44 inventor on multiple patents related to single cell and spatial genomics filed by or issued to the Broad 45 Institute.

- 46 47
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁴⁸ Summary

49 Altered myeloid inflammation and lymphopenia are hallmarks of severe infections, including 50 SARS-CoV-2. Here, we identified a gene program, defined by correlation with EN-RAGE 51 (S100A12) gene expression, which was up-regulated in patient airway and blood myeloid cells. 52 The EN-RAGE program was expressed in 7 cohorts and observed in patients with both COVID-53 19 and acute respiratory distress syndrome (ARDS) from other causes. This program was 54 associated with greater clinical severity and predicted future mechanical ventilation and death. 55 EN-RAGE⁺ myeloid cells express features consistent with suppressor cell functionality, with low 56 HLA-DR and high PD-L1 surface expression and higher expression of T cell-suppressive genes. 57 Sustained EN-RAGE signature expression in airway and blood myeloid cells correlated with 58 clinical severity and increasing expression of T cell dysfunction markers, such as PD-1. IL-6 59 upregulated many of the severity-associated genes in the EN-RAGE gene program in vitro, along 60 with potential mediators of T cell suppression, such as IL-10. Blockade of IL-6 signaling by 61 tocilizumab in a placebo-controlled clinical trial led to rapid normalization of ENRAGE and T cell 62 gene expression. This identifies IL-6 as a key driver of myeloid dysregulation associated with 63 worse clinical outcomes in COVID-19 patients and provides insights into shared 64 pathophysiological mechanisms in non-COVID-19 ARDS.

65

⁶⁶ Keywords

⁶⁷ Acute respiratory distress syndrome; COVID-19; myeloid; inflammation; lung injury; myeloid ⁶⁸ derived suppressor cells; IL-6; reverse translation; infectious disease; monocyte; neutrophil

⁶⁹ Introduction

70 Altered myeloid cell expression states, including the accumulation of cells with hallmarks of 71 myeloid-derived suppressor cells (MDSC), are consistent features in the blood of COVID-19 72 patients, and serve as a hallmark of severity (1-18). Monocytes and granulocytes associated with 73 increased COVID-19 severity exhibit low expression of HLA-DR, and high expression of hallmark 74 MDSC genes such as S100A12 (EN-RAGE), and can impair T cell activation via contact-75 dependent (i.e., PD-L1) and soluble mechanisms, including IL-10, TGF-B, arginase 1, IDO-76 dependent tryptophan metabolism, and reactive oxygen and nitrogen species (reviewed in (19-77 22)). Presence of MDSCs in severe COVID-19 patients, and patients with other severe infections, 78 correlates with reduced T cell numbers, and can impair T cell proliferation and IFN-y production 79 ex vivo (23–28). Reduced T cell proliferation and tissue sequestration can in turn contribute to the 80 lymphopenia observed in COVID-19 patients with severe disease, which increases with the 81 severity of respiratory failure and is prognostic for higher mortality (29). Thus, understanding the 82 role of myeloid suppressor cells and the pathways leading to their dysregulation is of critical 83 importance in COVID-19 and other infections.

84

The pathways driving myeloid inflammation and the mechanistic connection of maladaptive cellular programs to severe disease and response to drug interventions are not yet understood. IL-6 is a key regulator of inflammation and has been proposed as a potential driver of dysfunctional myeloid immune response in cancer, COVID-19, and other diseases (10, 12, 20, 26, 30–33). IL-6 treatment *in vitro* leads to differentiation of hematopoietic stem cells into CD14⁺ monocytes expressing a similar expression program to that observed in COVID-19 patient monocytes, including high expression of EN-RAGE and low expression of HLA-DR(10). Circulating IL-6

92 levels positively correlate with this severity-associated myeloid state in COVID-19 and other 93 severe infections(10). It has been suggested that treatment with IL-6-blocking antibodies 94 normalizes alterations in the myeloid compartment that are associated with disease severity(12), a 95 hypothesis requiring placebo-controlled trials to test. Samples from hospitalized COVID-19 96 patients treated with tocilizumab (a monoclonal antibody against IL6R/Actemra) in a placebo-97 controlled study (COVACTA, n=438 hospitalized COVID-19 patients with hypoxemia 98 randomized 2:1 tocilizumab:placebo) provided a unique opportunity to evaluate the role of IL-6 in 99 shaping myeloid inflammation in patients(34). A meta-analysis by the World Health Organization 100 concluded that IL-6 antagonists reduce 28-day mortality in patients hospitalized for COVID-101 19(35).

102

103 Here, we used single cell RNA-seq (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) 104 and bronchoalveolar lavage (BAL) fluid cells collected from COVID-19 patients, to identify a 105 myeloid cell program shared across tissue compartments, defined by high expression of the EN-106 RAGE gene, among other inflammatory markers. Expression of this program was associated with 107 more severe disease in our discovery cohorts. We replicated this finding using data from the 108 COMET observational study, which includes sampling from endotracheal aspirates (ETA), whole 109 blood, and PBMCs (2, 36, 37) of COVID-19 patients. Combined single cell profiling of RNA and 110 cell surface proteins (CITE-seq) characterized the immunosuppressive expression program in EN-111 RAGE signature expressing cells and connected it to cell surface phenotypes of impaired myeloid 112 antigen presentation and T cell dysfunction. The EN-RAGE expression program was associated 113 with several measures of COVID-19 clinical severity and outcomes and was also observed in 114 patients with acute respiratory distress syndrome (ARDS) from other causes, identifying a

targetable pathway relevant to ARDS. Finally, blocking IL-6 signaling using tocilizumab in an
 interventional setting reduced expression of the EN-RAGE signature and normalized T cell
 numbers in COVID-19 patients from the COVACTA trial, providing mechanistic insight into the
 therapeutic response to COVID-19 patients to IL-6 blockade.

- 119
- ¹²⁰ Results

A pan-myeloid EN-RAGE signature in blood and airway samples is associated with severe COVID-19

123 We used publicly available scRNA-seq data from COVID-19 patients to define a gene program 124 that classifies a shared myeloid state across airway and blood samples. We seeded the program by 125 the expression of the gene encoding EN-RAGE (S100A12), which has been implicated in several 126 myeloid populations in the peripheral blood associated with COVID-19 severity(2, 10, 38, 39). 127 EN-RAGE expression is upregulated by IL-6(40), is elevated in the airways of ARDS patients as 128 well as other lung diseases(41), and serum levels correlate with COVID-19 severity(1, 4). We 129 identified a set of 84 genes that co-vary (Pearson's r > 0.5) with EN-RAGE expression across 130 myeloid cells from bronchoalveolar lavage (BAL) fluid and PBMCs from COVID-19 patients(7, 131 11) (Figure. 1A; Table S1). This gene program showed strong coordinated expression across 132 airway and blood samples and predominant expression in many myeloid cell types (monocytes, 133 neutrophils, and macrophages), although dendritic cells (DCs) and non-classical monocytes 134 showed lower overall expression (Figure. S1). Increased expression of the EN-RAGE program in 135 neutrophil, monocyte and macrophage subsets was associated with greater clinical severity in both 136 blood and airway samples (Figure. 1B and Figure. S1C).

138	The EN-RAGE program scores correlated with the scores of a previously-defined MS1 gene set
139	(9), which was associated with increased severity in COVID-19 and sepsis patients(9, 10)
140	(Spearman's ρ =0.64 and 0.95 in pseudobulk expression profiles of blood and airway monocytes
141	and neutrophils (5 cohorts) and ρ =0.65 in whole lung myeloid cells (one cohort) (all p<0.0001)).
142	Only seven genes (CLU, CYP1B1, LILRA5, NAMPT, S100A12, S100A8, VCAN) are shared
143	between the 84 genes in the EN-RAGE program and the 23 genes in the MS1 signature identified
144	in COVID-19 patients(10), which is a significant overlap (p-value=7e-14, hypergeometric test).
145	EN-RAGE program expression was more highly intercorrelated than the MS1 signature across
146	sample types (Figure. S2A). While MS1 had strong pairwise correlations in PBMC myeloid cells,
147	many genes were no longer correlated when measured in whole blood (WB) or endotracheal
148	aspirate (ETA) (Figure. S2B-M). Because of the reduced performance of MS1 outside of PBMCs,
149	we used the EN-RAGE program (denoted EN-RAGE ⁺) in subsequent analyses to more specifically
150	evaluate myeloid cells in bulk RNA-seq from whole blood and airway samples, which have greater
151	cellular complexity than PBMC samples.

152

¹⁵³ EN-RAGE signature is associated with acute lung injury from diverse causes

¹⁵⁴ We next hypothesized that the EN-RAGE myeloid program may also be a feature of non-COVID-¹⁵⁵ 19 lung injury. To test this hypothesis, we scored the EN-RAGE program in samples from the ¹⁵⁶ COMET observational cohort, where 75 patients with either COVID-19 or acute lung injury from ¹⁵⁷ other causes were followed longitudinally (**Table 1**, patient characteristics)(2, 36, 37). Whole ¹⁵⁸ blood (WB), PBMC, and endotracheal aspirates (ETA) were sampled and profiled by scRNA-Seq. ¹⁵⁹ This cohort offers rich clinical and molecular phenotyping to allow single-cell dissection of the ¹⁶⁰ connection between the airways and the blood at the mRNA and protein level, and how this relates

161	to clinical outcomes. EN-RAGE signature expression was highest in monocytes, macrophages,
162	and neutrophils, consistent with our previous analyses (Figure 2 and Figure S2). EN-RAGE ⁺
163	myeloid cells were present in the blood and airways in both COVID-19 and non-COVID-19 acute
164	lung injury patients, highlighting the generality of this program (Figure 2C).
165	
166	EN-RAGE signature expression correlates with clinical severity and is prognostic for worse
167	clinical outcomes
168	In COVID-19 patients, EN-RAGE ⁺ myeloid cells were associated with increased clinical severity
169	at presentation, as defined by the extent of respiratory support required at study enrollment, in
170	monocytes (PBMC, Figure 2C and Figure S1C) and neutrophils (whole blood, Figure 2C). The
171	severity association of monocyte ENRAGE score observed in PBMC was not observed in the
172	smaller number of samples available from whole blood. An association with severity is not found
173	in ETA samples, perhaps since this sample type is only obtained from critically ill patients on
174	mechanical ventilation and so a milder severity group is lacking.
175	
176	We next asked whether higher EN-RAGE signature expression predicts worse patient outcomes.
177	In PBMC samples from COVID-19 and non-COVID-19 patients at COMET study enrollment, the
178	EN-RAGE program score was associated not only with greater baseline clinical severity (NIH
179	COVID-19 severity ordinal score) but also worse clinical outcomes (ICU admission p<0.01and
180	maximal NIH ordinal scale: Spearman ρ =0.30 p=0.02) (Figure 3A and Figure S3A-C). However,
181	these associations were no longer significant once baseline severity measures were considered in
182	our analyses (p>0.5, data not shown), possibly because of the limited numbers of patients in this
183	cohort and the increased risk of severe outcomes in patients presenting with greater severity. EN-

¹⁸⁵ nor with days from symptom onset to study enrollment (Spearman ρ =0.09, p=0.57). EN-RAGE ¹⁸⁶ score was higher in patients who presented with or later developed ARDS compared with those ¹⁸⁷ who did not by either AECC or Berlin diagnostic criteria (p<0.01 for AECC definition, p<0.05 for ¹⁸⁸ Berlin definition) (**Figure S3D-E**). ENRAGE score was higher in ARDS (AECC definition) ¹⁸⁹ resulting from SARS-CoV-2 infection or other etiology (p<0.05) (**Figure 3B**), but the difference ¹⁹⁰ in the smaller patient subgroups was not significant when using the more stringent Berlin ARDS ¹⁹¹ definition (**Figure S3F**).

192

193 Leveraging the availability of longitudinal samples from ventilated patients in the COMET cohort, 194 there was a significant association between the temporal trajectory of airway EN-RAGE 195 expression in each patient and patient outcomes (Figure 3C). To test this, we stratified patients 196 into two groups by the number of ventilator-free days (VFD) and compared the slope of the 197 regression lines of the two groups. Airway EN-RAGE expression decreased over time in survivors 198 with fewest days of ventilation and increased in patients who died or had ≥ 28 days of ventilation 199 (p<0.05 linear mixed model, ETA, Figure 3C). Worse clinical outcomes are accompanied by 200 sustained elevated airway levels of EN-RAGE⁺ cells as well as higher baseline levels in the blood. 201

EN-RAGE program expression in myeloid cells is associated with increased markers of immunosuppression in blood and airways

The EN-RAGE program score was also associated with expression of genes characteristic of MDSCs, suggesting one path through which EN-RAGE⁺ cells may contribute to clinical severity. Specifically, EN-RAGE program expression was correlated with metrics of suppressed myeloid

207	and lymphoid states across another five COVID-19 cohorts(2, 5, 7, 11, 12, 36, 37), spanning ETA,
208	BAL, lung, PBMC, and blood samples (complete results in Table S2). For example, in COMET
209	PBMC monocytes, EN-RAGE program expression correlated with high CD14 (Spearman ρ =0.65,
210	p<0.001), CCR2 (ρ=0.25, p<0.05) and PTGER2 (ρ=0.38, p<0.001) (Figure 3D). CCR2 and
211	PTGER2 are two receptors important for myeloid cell recruitment to the infected lung via CCL2
212	and prostaglandins, respectively. EN-RAGE program expression correlated with low expression
213	of MHC class II genes, suggesting reduced capacity for antigen presentation (HLADRA: ρ =-0.45
214	and <i>HLADRB1</i> : ρ =-0.48, p<0.001, Figure 3D and Table S2). In blood monocytes, there was a
215	positive correlation with STAT3, a key transcription factor regulating MDSC gene expression
216	(ρ=0.79, p<0.001, Figure 3D). MDSCs can suppress T cells using context-specific mechanisms
217	across sites of infection or malignancy, and the mechanisms used can also differ depending on
218	whether they originate from the monocytic or granulocytic lineage(13, 20). In blood monocytes,
219	EN-RAGE program expression was positively correlated with expression of genes encoding
220	effectors that can suppress T cells through reactive oxygen species (CYBB/PHOX) and
221	prostaglandins (<i>PTGER2</i>), and <i>TGFβ1</i> , but inconsistent associations with arginase (<i>ARG1</i>) and
222	tryptophan depletion (<i>IDO1</i>) across cohorts (Figure 3D and Table S2). Granulocytic EN-RAGE ⁺
223	cells had similar associations as their monocytic counterparts, with notable differences including
224	stronger correlations with <i>PDL1</i> and <i>TGFβ1</i> and little to no association with reactive oxygen
225	species (CYBB/PHOX) and PTGER2 compared with EN-RAGE ⁺ monocytes (Figure 3D and
226	Table S2). Consistent with MDSCs characterized in other infections and cancers(20, 22, 42), EN-
227	RAGE ⁺ cells expressed higher levels of multiple potential mediators of immunosuppression
228	(PDL1, CYBB/PHOX, and TGF β 1) with some genes preferentially expressed by monocytic
229	lineages (i.e. <i>CYBB/PHOX</i> ρ >0.4, Table S2) or granulocytic lineages (i.e. <i>TGF</i> β 1 ρ >0.6, Table

233

234 These associations were also largely observed in airways samples, suggesting an overall consistent 235 phenotype in both the blood and the infected lung (Figure 3D). As in the blood, EN-RAGE 236 program expression in monocytes and neutrophils was positively correlated with, STAT3 in ETA 237 samples but lacked the correlations with CCR2 and HLADR, showed stronger correlations with 238 CCR5, and inconsistent relationships with CYBB and CD14 (Figure 3D and Table S2). EN-239 RAGE⁺ monocytes and neutrophils cells in lung and airway samples (ETA, BAL, and lung post-240 mortem autopsy tissue) had increased association with PDL1, IL10, TGFB, IDO, and IL1B, which 241 can suppress T cell function, compared to the blood (Figure 3D,F and Table S2). Peripheral blood 242 myeloid cells expressed lower levels of IL10 and $IL1\beta$ and had weaker correlation with the EN-243 RAGE signature when transcripts were detected, illustrating the importance of sampling infected 244 tissues and establishing blood correlates of tissue immune responses (Figure 3D and Table S2). 245 Across four patient cohorts, airway EN-RAGE⁺ monocytes and neutrophils consistently expressed 246 multiple markers of inflammation with autoregulatory functions that can be immunosuppressive, 247 including IL10, PDL1, TGF\$1, IL1\$, and IDO (Table S2).

248

²⁴⁹ Characterization of EN-RAGE⁺ myeloid and T cell phenotypes

²⁵⁰ To connect the EN-RAGE expression program to cellular phenotypes, we used CITE-seq data ²⁵¹ from PBMCs in COMET to relate cell surface protein expression and EN-RAGE program ²⁵² expression. The EN-RAGE signature was most highly expressed in CD14⁺CD16^{lo}HLA-DR^{lo}

253 classical monocytes (cM) (Figure 4A-B), confirming the reduced antigen presentation capacity 254 suggested by scRNA-seq data (Table S2). EN-RAGE signature scores on cMs positively 255 correlated across patients with cM surface expression of 19 of the 188 CITE-Seq measured 256 proteins (FDR<0.05, Figure 4C), including three markers characteristic of MDSCs: PD-L1 257 (CD274, Spearman p=0.43, FDR=0.008), podoplanin (PDPN, p=0.52, FDR=0.001), and CD38 258 (p=0.49, FDR=0.002), which is IL-6-inducible in tumors(43, 44). Conversely, EN-RAGE 259 signature scores on cM were negatively correlated with 19 markers (FDR<0.05, Figure 4C), 260 including HLA-DR (ρ =-0.73, FDR<0.0001), the T cell costimulatory protein CD40L (ρ =-0.36, 261 FDR=0.03), the LFA subunit CD11A involved in trafficking and activation (ITGAL, ρ =-0.52, 262 FDR=0.002), and two markers of granulocytic MDSCs (SIGLEC7: p=-0.52, FDR 0.001; CD244: 263 ρ=-0.50, FDR=0.002) (**Figure 4C**).

264

EN-RAGE program scores in cMs also negatively correlated with the level of the activation marker CD40 on CD4⁺ T cells (**Figure 4D**), consistent with the negative correlation of the expression of ligand CD40L on cMs with their EN-RAGE program (**Figure 4C**). Conversely, EN-RAGE program scores in cMs were positively correlated with two proteins expressed by exhausted CD4⁺ and CD8⁺ T cells: podoplanin/PDPN (Spearman ρ =0.37, FDR=0.04) and TNFSF14/LIGHT (ρ =0.39, p=0.03) (**Figure 4D-E**). These data support the EN-RAGE program activity in cMs correlating with distinct CD8⁺ and CD4⁺ T lymphocytes activation states across patients.

272

²⁷³ Moreover, the dynamic changes in EN-RAGE program expression and markers of myeloid ²⁷⁴ activation and T cell dysfunction were associated with clinical outcomes. Patients with PBMC ²⁷⁵ CITE-seq data were categorized into 4 outcome groups based on survival and the duration of

276	mechanical ventilation. In monocytes from patients with more severe outcomes compared with
277	patients not requiring ventilation, HLA-DR trended lower than healthy (indicated by red line) and
278	failed to recover to healthy levels over 14 days (Figure 4F), and trends of sustained higher PD-L1
279	and EN-RAGE score in some greater severity groups remained higher in ventilated patients
280	(Figure 4G-H). On CD8 ⁺ and CD4 ⁺ T cells, markers of T cell dysfunction or exhaustion (PD-1,
281	LAG3, TIGIT, CTLA4, and BTLA4) showed greater increases over 14 days in patients with
282	worsening outcomes (>7 days mechanical ventilation and/or death) compared with non-ventilated
283	patients (Figure 4I-L and Figure S4, Pearson correlation p<0.05, not significant for PD-1 on CD4 ⁺
284	T cells). Therefore, the EN-RAGE myeloid expression program correlates with markers of a
285	suppressive cell surface phenotype on monocytes, and with reduced activation of CD4 ⁺ and CD8 ⁺
286	T cells, as indicated by increasing expression of T cell dysfunction markers over time (Figure 4I-
287	L and Figure S4).

288

²⁸⁹ *IL-6 induces the EN-RAGE program in monocytes in vitro*

Several lines of evidence led us to hypothesize that IL-6 can be a regulator of the EN-RAGE program. First, IL-6 treatment of HSPCs promotes upregulation of the MS1 gene signature in monocytes(10), which correlates with the EN-RAGE program (Spearman $\rho \ge 0.64$ in monocytes, p<0.0001 across 5 cohorts as described above). Moreover, blood monocyte EN-RAGE program expression correlates with plasma IL-6 protein levels, and with levels of monocyte *STAT3* mRNA, a transcription factor activated by IL-6 signaling (**Figure 3D-E** and **Table S2**). To test this hypothesis, we treated human primary monocytes with IL-6 *in vitro* followed by RNA-seq.

298	IL-6 treatment altered the expression of 36 of 84 EN-RAGE program genes (Benjamini-Hochberg
299	FDR<0.05, Figure 5A), as well as of <i>IL10, IL1β, CYBB</i> , and <i>CCR2</i> (Figure 5B), all features of
300	EN-RAGE ⁺ monocytes in COVID-19 patients (Figure 3D). Using gene set enrichment analysis,
301	we found that IL-6 could partially up-regulate the expression of EN-RAGE and MS1 signature
302	genes (Benjamini-Hochberg adjusted p<0.001 and p<0.01, respectively; Figure 5C). Our data
303	suggest that IL-6 is sufficient to upregulate the expression of many ENRAGE program genes in
304	monocytes in vitro, including markers of a potentially T cell suppressive phenotype in patients.
305	

³⁰⁶ The myeloid EN-RAGE program correlates with expression programs of suppressive myeloid ³⁰⁷ cells and impaired T cells and with increased clinical severity in an interventional COVID-19 ³⁰⁸ clinical trial

309 We next asked if blocking IL-6 signaling in patients correlated with a change in EN-RAGE 310 program expression, leveraging data from COVACTA, a double-blind randomized clinical trial of 311 tocilizumab (anti-IL6R/Actemra) in hospitalized COVID-19 patients with hypoxemia(34). 312 Consistent with our findings in other cohorts, bulk RNA-seq expression profiles from whole blood 313 collected at baseline from 438 patients showed higher normalized enrichment scores for the EN-314 RAGE program in patients requiring positive pressure ventilation at baseline compared with those 315 who did not (Figure 6A-B, FGSEA Benjamini-Hochberg FDR < 0.05). The EN-RAGE gene set 316 was also enriched in patients needing future mechanical ventilation or progressing to death even 317 when controlling for the association with baseline severity (Figure 6C-D, FGSEA Benjamini-318 Hochberg FDR<0.05). The prognostic relationship of the ENRAGE signature with mortality was 319 maintained even when adjusting for myeloid cell proportions in blood (Figure S5A-E; FDR<0.05, 320 FGSEA). Moreover, lower expression of gene sets classifying CD8⁺ and CD4⁺ T lymphocytes

321	(CIBERSORT(45)) was associated with worse clinical severity and outcomes (Figure 6B-D,
322	(Benjamini-Hochberg FDR<0.05). Furthermore, consistent with COMET whole blood scRNA-
323	seq, EN-RAGE program scores were positively correlated with expression of PDL1, IL10, and
324	<i>IL1</i> β in whole blood at day 1 in COVACTA patients (Figure 7A), as well as with serum protein
325	levels of EN-RAGE, IL-6, IL-10, IL-1β, and ARG1 (Figure S7A, t-test p<0.05). Examination of
326	T cell genes that were associated with EN-RAGE program expression in scRNA-seq data (Figure
327	7A) revealed that high myeloid EN-RAGE program expression in COVACTA bulk RNA-seq was
328	associated with low expression of T cell effectors (granzyme, perforin and lymphotoxin (GZMB,
329	GZMM, PRF1, LTA)), cytotoxicity (FASL), and IFNG), activation markers (KLRK1/NKG2D) and
330	dysfunction markers (CTLA4, LAG3, CD160). Many of these genes were expressed at a lower
331	level in patients with more severe disease (IFNG, FASLG, CTLA4, LAG3, TIGIT, TBX21/Tbet,
332	XCL1; Figure 7B, Benjamini-Hochberg FDR<0.05 and fold change < log ₂ -0.5). Higher EN-
333	RAGE program expression was also correlated with lower lymphocytes (ρ =-0.5) and monocytes
334	(ρ =-0.2) and increased neutrophils (ρ =0.5) (Figure S7A, all p<0.001). Thus, the COVACTA
335	cohort shows similar features to those observed in COMET, including the expression of the EN-
336	RAGE ⁺ myeloid program and its correlation with greater clinical severity and worse clinical
337	outcomes.

338

IL-6 blockade decreases the myeloid EN-RAGE state and increases T cells in COVID-19 patients

³⁴¹ Finally, to understand the role of IL-6 in patients, we examined the effect of tocilizumab treatment ³⁴² on the EN-RAGE myeloid state in COVID-19 patients and effect on T cells using longitudinal ³⁴³ samples from the COVACTA study(14, 34). Blockade of IL-6 signaling reduced expression of

344 many genes in the EN-RAGE program and increased T cell signature expression after 3 or 7 days 345 of tocilizumab treatment compared with placebo (Figure 6A, E; Benjamini-Hochberg FDR<0.05). 346 Consistent with the EN-RAGE program expression, MDSC and MS1 signatures were elevated in 347 patients with worse baseline clinical severity and needing future mechanical ventilation or who 348 died, and decreased following tocilizumab treatment (Figure 6B-E, Benjamini-Hochberg 349 FDR < 0.05). These enrichments were consistently maintained when adjusted for blood cell type 350 composition (proportion of total leukocyte levels added as covariates to the DESeq2 model) 351 (Figure S5A-C). The effect of tocilizumab on gene set enrichment was comparable between 352 tertiles of baseline serum IL-6 protein levels (Figure S5D-E). EN-RAGE program gene expression 353 was sustained over the first 7 days in patients with worse clinical outcomes at day 28 (hospitalized 354 or non-survivor vs discharged, Figure 6F). The ENRAGE program was reduced following 355 tocilizumab treatment more than in placebo treatment over the first 7 days, particularly in patients 356 with better clinical outcomes (Figure 6F and Figure S6A). At the same time, CD8 T cell-357 associated gene expression rapidly increased after tocilizumab treatment, again particularly in 358 patients that showed clinical improvement (Figure 6F and Figure 7C). Similar results were 359 observed for the MS1 severity-associated myeloid and CIBERSORT CD4⁺ T cell gene sets 360 (Figure S6B, D). This corresponded with a more rapid increase in blood lymphocytes and decrease 361 in neutrophil cell counts in tocilizumab-treated patients who were discharged by 28 days compared 362 with placebo (Figure S6E-J). When we compared the change between day 7 and 1 in EN-RAGE 363 program expression with the change in measured blood cellularity, patients with a greater decrease 364 in EN-RAGE had a greater increase in blood lymphocytes and monocytes and decreases in 365 neutrophils (Figure S7B-D). This was more pronounced in patients treated with tocilizumab 366 compared with placebo.

367

368 The reduction in EN-RAGE program following IL-6 blockade corresponded with normalization 369 of potential mediators and correlates of T cell suppression. Patients with a greater decrease in EN-370 RAGE program expression from day 1 to 7 had greater decreases in serum EN-RAGE, IL-10, IL-371 1β, and ARG1 protein levels, as indicated by a positive slope of the correlation line (Figure S7E-372 H). IL-6R blockade with tocilizumab resulted in a greater decrease in ENRAGE program 373 expression, as indicated by a greater offset in the regression in the tocilizumab-treated arm 374 compared with placebo, and a greater decrease in this set of serum proteins, as indicated by more 375 green vs red dots in the bottom left quadrant (Figure S7E-H). This correlated with increased 376 expression of the T cell genes IFNG, FASLG, CTLA4 and XCL1 in tocilizumab-treated patients 377 (Figure 7C). In sum, blockade of IL-6 signaling in COVID-19 patients rapidly normalizes the 378 severity-associated myeloid and T cell states, identified using both patient scRNA-seq data and 379 the IL-6 in vitro model, to levels in healthy individuals, which correlates with clinical improvement 380 by 28 days.

381

382 383383Discussion

³⁸⁴ While altered myeloid states are hallmarks of COVID-19 disease severity(1–18), the ³⁸⁵ pathways driving maladaptive myeloid inflammation have not been clearly defined. This study ³⁸⁶ supports a working model whereby IL-6 differentiates myeloid cells from both monocytic and ³⁸⁷ granulocytic lineages to a suppressive phenotype characterized by low antigen presentation on ³⁸⁸ HLA-DR and increased expression of multiple factors that can suppress T cells (IL-10, PD-L1, ³⁸⁹ TGF-β1) (**Figure 7D**). We define a pan-myeloid ENRAGE program of coordinately-expressed ³⁹⁰ genes in the airways and blood of COVID-19 patients that is prognostic for severe outcomes and

391 is robust across 7 cohorts(2, 5–7, 11, 12, 14, 36, 37). EN-RAGE⁺ cells express multiple phenotypic 392 hallmarks of MDSCs by cell surface protein analysis: decreased capacity for antigen presentation 393 and co-stimulation through HLA-DR and CD40, and increased potential to suppress T cells 394 through PD-L1. This was associated with sustained elevated expression of markers on T cells 395 dysfunction such as PD-1 in patients with prolonged mechanical ventilation or who died. COVID-396 19 patients with higher EN-RAGE signature expression had a greater risk of future mechanical 397 ventilation and mortality, and EN-RAGE⁺ myeloid cell impairment of optimal T cell-mediated 398 immunity is one potential mechanism.

399 These data demonstrate the importance of IL-6 in altering immune cell phenotypes in 400 COVID-19 patients and provide a potential mechanism for the therapeutic benefit of tocilizumab 401 in patients hospitalized with COVID-19(35). Tocilizumab is approved for treating hospitalized 402 adult COVID-19 patients requiring supplemental oxygen and receiving corticosteroids by the US 403 Food and Drug Administration and the European Medicines Agency. IL-6 antagonists significantly 404 reduced mortality compared with usual care in a large meta-analysis using data from 27 trials(35). 405 While COVACTA did not meet the primary endpoint of improving clinical status on day 28, 406 tocilizumab demonstrated clinically meaningful benefits, such as shortening hospital stay by 8 407 days, compared with the placebo arm(34). Therapeutic blockade of IL-6 signaling with 408 tocilizumab attenuates expression of the EN-RAGE signature in blood cells and normalize T cell 409 numbers, correlating with clinical improvement. IL-6 alone does not significantly induce the entire 410 ENRAGE program, which is consistent with the partial IL-6R-dependent induction of the severity-411 associated MS1 program by sepsis patient serum using an *in vitro* system(10). The effect of IL-6R 412 blockade in reducing the ENRAGE signature expression in patients was observed in survivors and

not non-survivors (Figure 6F), suggesting other potential factors besides IL-6 that regulate
 expression of the full severity-associated transcriptional program.

415 COVID-19 patients with lymphopenia are at higher risk for worse clinical outcomes in the 416 COVACTA cohort(29). In addition to being reduced in numbers, suppressed T cell phenotypes 417 have been described in severe COVID-19 patients. Polyfunctional Th1 and Th17 CD4⁺ and CD8⁺ 418 cell subsets are underrepresented in SARS-CoV-2 infection, with less proliferation and impaired 419 IFN-y and IL-2 secretion following restimulation in vitro(46, 47). T cells with increased expression 420 of activation (OX40, CD69) and exhaustion (PD-1, TIGIT, TIM1) markers have been observed in 421 some(38, 48) but not all cohorts(49) and functional exhaustion of CD8⁺ T cells has been 422 reported(50–52). In single cell analysis of the COMET cohort, a phenotype of sustained elevated 423 expression of PD-1, TIGIT, and LAG3 was observed on T cells in patients requiring longer 424 mechanical ventilation and non-survivors. As tocilizumab increased the number of circulating T 425 cells, the observed increase in markers of T cell function such as IFNy and CD69 may result from 426 increased T cell abundance rather than increased functionality per cell. Differential regulation of 427 T cell genes suggests a potential effect of tocilizumab on T cell quality in addition to quantity. IL-428 6R blockade increases markers of early polyfunctional T cells (IFNG, XCL1, CD69) and recently 429 activated/less exhausted cells (IL7R) while markers associated with broader spectrum of T cell 430 functional states (i.e. cytotoxic T cell markers T-bet (TBX21), perforin (PRF1), and granzymes 431 (GZMM, GZMB)) are less affected. However, there is limited ability to infer T cell functionality 432 from bulk RNA-seq data. Future studies using multi-dimensional flow cytometry data will enable 433 more precise definition of how IL-6 alters the T cell phenotype in COVID-19, both via myeloid 434 activation and acting directly on T cells. NK cells are important antiviral effector cells that can be 435 suppressed by MDSCs(19) and can express markers of dysfunction in COVID-19(49). A potential

connection between EN-RAGE+ myeloid cells and NK cells or the suppressive regulatory T cell
 phenotype observed in severe COVID-19 patients(53) remains to be characterized.

438 Suppressive myeloid cells are one potential mechanism underlying impaired T cell 439 immunity in severe COVID-19. MDSCs express mediators of T cell suppression in a context-440 dependent manner, depending on the type of infection or tumor(20, 22). MDSCs express multiple 441 genes through which they may potentially suppress T cells. Moreover, differential correlations 442 between the EN-RAGE signature and genes encoding immunosuppressive mediators were 443 observed between cell lineage (granulocytic vs. monocytic) and compartment (blood vs. airways). 444 MDSCs are often identified by low HLA-DR expression as a marker of impaired antigen 445 presentation capacity(23, 26–28, 46). Interestingly, while some features of EN-RAGE⁺ cells were 446 consistent between blood and airways (i.e. high PD-L1), the expression of other genes was tissue-447 dependent, and the low expression of HLA-DR in the blood was lost in airway samples. This is 448 consistent with the observation that HLA-DR¹⁰ MDSCs were not found in ETA airway samples by 449 flow cytometry(26). These data suggest that EN-RAGE⁺ myeloid cells home to the infected lung 450 and adopt a tissue-specific phenotype, with increasing expression of IL-10 and IDO and decreasing 451 expression of CCR2 and CYBB, highlighting the importance of characterizing immune responses 452 at the site of infection. The EN-RAGE⁺ myeloid state may underlie disease severity through 453 additional mechanisms. For example, EN-RAGE⁺ cells express higher *IL-1* β and *TGF-\beta1* which 454 can increase endothelial and epithelial cell permeability, respectively, and potential mechanisms 455 whereby EN-RAGE⁺ cells could affect barrier integrity and edema in patients with acute lung 456 injury remains to be explored (10, 54, 55).

This study connects immune cell phenotypes in the blood with the myeloid EN-RAGE state in the airways using paired quantification of mRNA and surface proteins at single cell

459 resolution in PBMCs and ETA single cell transcriptomes from the COMET study and longitudinal 460 blood mRNA expression data from the large Phase 3 COVACTA study. The inclusion of patients 461 with acute lung injury from other causes in the COMET cohort reveals that EN-RAGE⁺ myeloid 462 cells are relevant to insults in addition to SARS-CoV-2 infection, and identifies a targetable 463 pathway relevant to ARDS. IL-6 predicts severe patient outcomes(29) and has been hypothesized 464 to be a driver of myeloid differentiation in severe infections (10, 12). We show that tocilizumab 465 treatment rapidly normalized myeloid and T cell states to healthy control levels, which was 466 correlated with improved clinical outcomes. This study establishes the importance of IL-6 in 467 driving differentiation of the severity-associated EN-RAGE⁺ myeloid state in patients. COVID-19 468 and cancer share risk factors, such as age and metabolic syndrome, and underlying 469 immunobiology, such as MDSCs and T cell dysfunction, making it appealing to speculate that EN-470 RAGE⁺ myeloid cells may contribute to pathology in multiple diseases.

⁴⁷¹ Methods

⁴⁷² *Reanalysis of published scRNA-seq data*

473 Schulte-Schrepping, downloaded Raw count data from et al.(11)were from 474 http://fastgenomics.org. For analysis of the PBMC data collected using 10x Genomics droplet-475 based capture, and whole blood collected using Rhapsody microwell-based capture, the raw count 476 data was reprocessed using scripts written in the R programming language(56) and packages from 477 the Bioconductor project (https://www.bioconductor.org). Briefly, counts were normalized using 478 the computeLibraryFactors method from the scater R package(57) and dimensionality reduction 479 was performed using PCA followed by UMAP projection. For calculating PCA, the top 5000 most 480 variable genes were selected, accounting for overall expression level using the modelGeneVar 481 method from the scran R package(58). The UMAP projection was calculated using the first 10 482 principal components. Graph-based clustering was performed using the Louvain algorithm on the 483 same 10 principal components. Marker genes for each cluster were determined using pairwise t-484 tests, calculated using the pairwiseTTest method from the scran R package, and were used to 485 manually assign broad cell type labels to each cluster. Clusters from the same broad cell type 486 classification were merged. The myeloid populations (monocytes, DCs and neutrophils) were 487 separately re-clustered using the same procedures: the 5000 most variable genes were selected, 488 used for PCA calculation, graph-based clustering and UMAP projection. Marker genes were 489 calculated for each cluster, and clusters were manually assigned using the marker gene lists.

490

⁴⁹¹ Raw sequencing reads from Liao, *et al.*(7) were downloaded from SRA (PRJNA608742).
⁴⁹² Sequencing data were then processed using cellranger v4.0.0 (10x Genomics, Pleasanton, CA,
⁴⁹³ USA) using GRCh38 as the reference genome, and gene models from GENCODE (v27) for

494 assigning reads to genes. The emptyDrops method was used from the DropletUtils R package(59) 495 to identify barcodes that corresponded to cellular droplets. Any barcode with fewer than 200 UMIs 496 or 100 genes detected was removed. This allowed us to retain neutrophil-containing droplets, as 497 these are mostly removed by default processing using cellranger. Droplets with high abundance of 498 mitochondrial RNA (>10%) were removed. This yielded 90592 cells for further analysis. The same 499 procedures described above were used to normalize, cluster and annotate cells into broad 500 populations (macrophage, neutrophil, T cell, epithelial cell, B cell). The myeloid populations 501 (macrophages and neutrophils) were selected and reclustered into more fine-grained populations 502 using the same strategy as above.

503

504 Data from Silvin, et al.(12) were retrieved from the European Genome Archive (EGA) under 505 accession number E-MTAB-9221 as FASTQ files. Sequencing data were processed as detailed 506 above for PRJNA608742, using the same parameters for identifying cellular droplets and filtering 507 droplets with high mitochondrial RNA abundance. Normalization, clustering and manual 508 annotation was performed as described above. Count data from Delorey, et al.(5) were downloaded 509 from the Broad Single Cell Portal using accession number SCP1052. We used the cell annotations 510 as defined within that dataset, selecting cells labeled as Myeloid using the Cluster field defined by 511 the authors. Data from Grant, et al.(6) were retrieved from the Gene Expression Omnibus (GEO) 512 under accession number GSE155249. Normalization and clustering were performed as above. 513 Annotations from the original publication were used to group cells into broad lineages: epithelial 514 cells, B cells, T cells, dendritic cells, mast cells, macrophages and mixed myeloid cells.

515

⁵¹⁶ *Pseudobulk expression profile calculation*

The aggregateAcrossCells method from the scater R package(57) was used to calculate pseudobulk expression profiles for each cell population in a sample. This method uses the sum of raw counts to determine an estimate of the aggregate expression of that cell type in a sample. The TMM method from the edgeR R package(60) was used to normalize the pseudobulk count data within each dataset. Signature score calculation in pseudo-bulk data was performed as previously described(61) using the GSDecon package (https://github.com/JasonHackney/GSDecon).

523

⁵²⁴ COMET PBMC CITE-seq analysis

525 The raw scRNA-seq counts were normalized using the 'LogNormalized' method implemented in 526 the 'NormalizeData' function from the Seurat R package(62); with this method, the feature counts 527 are divided by the total counts for each cell, multiplied by a scale factor of 10,000, and then natural-528 log transformed. The raw ADT counts were normalized using the 'CLR' method implemented in 529 Seurat's 'NormalizeData' function; with this method, a centered log ratio transformation is 530 applied. The ENRAGE and MS1 gene set scores were calculated for each cell using the 531 'score genes' function implemented in the scanpy Python package(63). All of the pseudobulk 532 values for each cell population in a sample (i.e., sample + cell type)—that is, the mRNA 533 expression, ADT expression, and gene set scores—were calculated as the average across all cells 534 in that population. Correlations between gene set scores and ADT expression were on pseudobulk 535 data and refer to a population of cells across patients.

536

⁵³⁷ Identification of EN-RAGE gene expression induced by IL-6 in vitro.

⁵³⁸ PBMCs were isolated from 50 mL of heparinized blood of four healthy donors by Ficoll-Paque.
 ⁵³⁹ Primary human monocytes were purified from PBMC by Miltenvi Pan Monocyte Isolation Kit and

540 cultured in RPMI with 10% heat-inactivated FBS, 10 mM HEPES and L-glutamine. The primary 541 human monocytes were stimulated with 10 ng/mL IL-6 + 18.7 ng/mL IL6R for 24 hours, and 542 RNA-seq performed on bulk cells. Unsupervised clustering using average linkage cluster 543 difference and Euclidean point distance metrics were used to generate heat maps. RNA was 544 isolated using the Qiagen RNeasy 96 kit (Qiagen catalog: 74182). Total RNA was quantified with 545 Qubit RNA HS Assay Kit (Thermo Fisher Scientific catalog: Q32852) and quality was assessed 546 using RNA ScreenTape on 4200 TapeStation (Agilent Technologies catalog: 5067-5576). cDNA 547 library was generated from 2 nanograms of total RNA using Smart-Seq V4 Ultra Low Input RNA 548 Kit (Takara catalog: 634894). 150 picograms of cDNA was used to make sequencing libraries by 549 Nextera XT DNA Sample Preparation Kit (Illumina catalog: FC-131-1024). Libraries were 550 quantified with Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific catalog: Q32851) and the 551 average library size was determined using D1000 ScreenTape on 4200 TapeStation (Agilent 552 Technologies catalog: 5067-5582). Libraries were pooled and sequenced on the Illumina NovaSeq 553 6000 to generate 30 million single-end 50 base pair reads for each sample. Sequencing reads were 554 filtered and aligned using HTSeqGenie v4.4.2(64). GSNAP v2013-11-01 was used for alignment, 555 through the HTSeqGenie wrapper, against the GENCODE 27 Basic gene model on the human 556 genome assembly GRCh38. Only reads with unique genomic alignments were analyzed. 557 Normalized CPM (Counts Per Million) were used as a normalized measure of gene expression, 558 calculated using method provided in edgeR(60).

559

⁵⁶⁰ COMET cohort

The COVID-19 Multi-Phenotyping for Effective Therapies (COMET) cohort collected PBMCs,
 whole blood, ETA and plasma longitudinally from hospitalized patients presenting with COVID-

563	19 symptoms. This study included 75 patients with samples collected in 2020, of whom 57 were
564	positive (76%) for SARS-CoV-2, along with 11 healthy controls(2, 36, 37). Table 1 summarizes
565	the patient characteristics. All-cause mortality occurred within 30 days for 9 of 10 subjects.
566	Ventilator-free days (VFDS) were assessed at D28, with fatal cases assigned 0. NIH COVID-19
567	ordinal severity score and Sequential Organ Failure Assessment (SOFA) scores were assessed at
568	study enrollment (Day 0), when baseline samples were collected, with a 9 day median time from
569	symptom onset (4-13 IQR). Severity groups were defined as follows. PBMC: Moderate = no
570	supplemental O_2 , severe = supplemental O_2 and critical = mechanical ventilation. Whole blood:
571	Mild/Moderate = 0 days on ventilator and no more than 1 day in ICU, Severe patients had ≥ 1 day
572	on ventilator. ETA: Critical=VFDS=0 (ventilation for \geq 28 days or death), severe ETA=VFDS>0.
573	
574	PBMCs were isolated and single cell RNA sequencing and Cellular Indexing of Transcriptomes
575	and Epitopes by Sequencing (CITE-seq) data was generated as previously described(37), with cell
576	types defined by marker genes. The complete protocol is available on protocols.io
577	(https://www.protocols.io/view/10x-citeseq-protocol-covid-19-patient-samples-tetr-bqnqmvdw).
578	Data was generated for 188 unique cell surface antigens. CITE-seq data was included from 128
579	samples collected at day 0, day 7 and/or day 14 from 60 patients. Single cell RNA-seq data
580	generated from PBMC collected at day 0 from 49 patients, whole blood collected at day 0 for 18
581	patients, and 41 ETA samples collected longitudinally from 16 patients were included in this study.
582	Bulk gene expression data was generated from 182 samples collected longitudinally from 19
583	patients. Plasma cytokine and paired ETA scRNA-seq data was available for only 7 samples,
584	precluding correlation analyses.

⁵⁸⁶ COVACTA tocilizumab clinical trial

587 A total of 438 hospitalized COVID-19 patients were randomized 2:1 for anti-interleukin-6 receptor 588 antibody, tocilizumab, or placebo and included in the modified intention to treat population 589 (tocilizumab: 294, placebo: 144). Hospitalized patients were ≥ 18 years of age with COVID-19 590 pneumonia confirmed by a positive SARS-CoV-2 PCR test and evidenced by x-ray or computed 591 tomography (CT) scan. Eligible patients had a blood oxygen saturation of $\leq 93\%$ or partial pressure 592 of oxygen/fraction of inspired oxygen of <300 mm/Hg. Details of the COVACTA study design 593 have been published (Clinical trials.gov NCT04320615)(34). Population demographics for the 404 594 patients with available blood RNA-seq data are described in Table 1.

595

596 Serum IL-6 was quantified using a validated in vitro diagnostic method (Roche Cobas; Roche 597 Diagnostics, Indianapolis, IN) at central laboratories (PPD). Complete blood counts were 598 measured using standard clinical chemistry and haematology methods available at local hospital 599 laboratories. IFNy and IL10 were measured by qualified immunoassays (Simpleplex, 600 ProteinSimple, San Jose, CA, USA) at central laboratories (Covance). The Olink Explore platform 601 was used to measure 1472 serum proteins (Olink, Uppsala, Sweden). RNA was isolated from blood 602 PaxGene (Qiagen, Hilden Germany) samples by Q2 Solutions. 1.25 ug of RNA was used for 603 generating sequencing libraries with the TruSeq® Stranded mRNA Library Prep kit (Illumina, San 604 Diego, CA, USA). The libraries were sequenced by Illumina NovaSeq by 50 bp single-end reads 605 at a read depth of 50 million reads per sample.

606

⁶⁰⁷ For the time point comparisons (D1 to D7) patients were subset to those subjects with ⁶⁰⁸ measurements at both time points before differential expression analysis with DESeq2. Unfiltered

609	DESeq2 outputs were ranked by log2 fold change and then the FGSEA Bioconductor package was
610	used to calculate enrichment scores. We used the ggplot2 package to generate visualizations. T
611	cell genes with a relationship to EN-RAGE state in COMET scRNA-seq data were examined in
612	COVACTA, and limited to the subset of T cell suppressive genes that were predominantly
613	expressed by T cells in COMET whole blood transcriptome data to permit analysis of bulk gene
614	expression data. Computational methods are described in more detail elsewhere(14).

615

⁶¹⁶ *COVID-19 clinical severity*

617 Within the COVACTA clinical trial, the NIH COVID-19 ordinal severity scale was used to assess 618 disease severity: 3=hospitalized not requiring supplemental O₂, 4= supplemental O₂, 5= non-619 invasive/high flow O_2 , 6= mechanical ventilation, 7= mechanical ventilation + additional organ 620 support (eg, vasopressors, renal replacement therapy, ECMO), 8=death. In the COMET cohort of 621 PBMC samples, moderate = no supplemental O_2 (NIH ordinal scale 3-4), severe = supplemental 622 $O_2(5-6)$ and critical = mechanical ventilation (7). The maximal NIH ordinal severity scale recorded 623 during hospitalization was calculated for each patient in COMET. Ventilator-free days were 624 calculated over 28 days, with fatal patients scored as 0. ARDS was diagnosed using the American-625 European Consensus Conference (AECC) definition(65) or Berlin definition(66). The sequential 626 organ failure assessment (SOFA) score was calculated at study enrollment.

627

⁶²⁸ Statistical analysis

Gene expression was log₂ normalized. Patient demographics are given as median (IQR) and frequency (%). Medians and first and third quartile ranges are shown in box and whisker plots and medians are shown on dot plots. Longitudinal COVACTA line plots show means and 95%

632 confidence intervals. Two-sided unpaired t-tests were used to compare gene signature scores 633 between cell types in pseudobulk scRNA-seq data. Student's t-test was used to calculate p values 634 for comparisons of EN-RAGE gene set scores and clinical severity. A mixed linear model was 635 used to compare slopes of longitudinal EN-RAGE gene set expression between severity groups. 636 Spearman correlations and two-tailed p values were calculated to examine relationships between 637 biomarkers and clinical severity and EN-RAGE gene set vs. myeloid gene expression. False 638 discovery rates were calculated for differential expression analysis of bulk RNAseq data 639 (accounting for transcriptome-wide analysis of x genes), GSEA (accounting for the x gene sets 640 analyzed), and COMET PBMC CITE-seq data (accounting for 188 measured proteins), using the 641 Benjamini-Hochberg method. Biorenderer was used to generate some Figures.

642

⁶⁴³ *Study approval*

The COMET study was approved by the Institutional Review Board: UCSF Human Research Protection Program (HRPP) IRB# 20-30497 and informed consent was obtained for patients. COVACTA was conducted in accordance with Good Clinical Practice guidelines of the International Council for Harmonisation E6 and the Declaration of Helsinki or local laws and regulations, whichever afforded greater protection. Informed consent was obtained from the patient or their legally authorized representative prior to participation. The studies were approved by institutional review boards or ethics committees at each site.

651

652
653Data availability

⁶⁵⁴ The RNAseq and proteomics data that support the findings of this study are available in the public
 ⁶⁵⁵ online respositories Gene Expression Omnibus (GEO), SRA, and the European Genome-Phenome

656	Archive (EGA). COMET: GEO GSE163668 (whole blood), GSE163426 (tracheal aspirate),
657	GSE168453 (PBMC). Schulte-Schrepping, et al.: <u>http://fastgenomics.org</u> . Liao, et al.: SRA
658	PRJNA608742. Silvin, et al.: EGA E-MTAB-9221. Delorey, et al.: Broad Single Cell Portal
659	accession number SCP1052. Grant, et al.: GEO GSE155249. COVACTA RNA-seq, proteomics,
660	and clinical metadata: EGA; accession number EGAS00001006688 (available to qualified
661	researchers upon request; https://ega-archive.org/). Individual patient level clinical data for the
662	COVACTA study is available through the clinical study data request platform (https://vivli.org/).
663	

⁶⁶⁴ Code availability

⁶⁶⁵ No new algorithms were developed for this manuscript. Most of the analyses performed in this ⁶⁶⁶ study used published packages mentioned in the Methods, with the exception of the ⁶⁶⁷ EnhancedVolcano (<u>https://github.com/kevinblighe/EnhancedVolcano</u>) package used to generate ⁶⁶⁸ volcano plots. All code generated for analysis is available from the authors upon request.

⁶⁷⁰ Author Contributions

⁶⁷¹ C.M.R., J.A.H, and H.S. conceived of and designed the overall study. J.A.H., H.S., H.VH., C.O.,

⁶⁷² L.O., X.G., A.C., and C.M.R. performed and interpreted computational analyses. X.G. performed

⁶⁷³ in vitro experiments. X.G., N.W., A.Q., D.C., A.C., D.F.C., A.J.C., T.C., G.K.F., A.A.R., A.R.,

⁶⁷⁴ J.T., K.H., N.F.K., M.F.K., D.J.E., K.K., A.S., Z.L., C.S.C., P.G.W., R.G., E.M., A.B., B.S.Z.,

⁶⁷⁵ C.L., C.M.H., M.G.P.vdW, G.C.H., T.G., R.B., D.S.L., J.R.G., Y.S., R.P., A.O., A.W., C.J.Y.,

⁶⁷⁶ UCSF COMET Consortium, T.R., J.M.M., F.C., A.T., M.B., L.T., I.O.R., A.R., S.B.K., R.N.B.,

⁶⁷⁷ C.M.R. facilitated the COMET or COVACTA studies and providing data and/or critical feedback

on methods and results. C.M.R., J.A.H, and H.S. wrote the first draft of the manuscript. J.A.H is

listed first for defining the ENRAGE signature and responsible for analysis of COMET and public
 datasets, with H.S. responsible for analysis of the COVACTA study. All authors reviewed and
 approved the final manuscript.

682

⁶⁸³ Acknowledgements

684 This study was supported with funding from Roche, Inc. and federal funds from the Department 685 of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; 686 Biomedical Advanced Research and Development Authority, under OT number: 687 HHSO100201800036C. C.J.Y. is further supported by the NIH grants R01AR071522, 688 R01AI136972, U01HG012192, and the Chan Zuckerberg Initiative, and is an investigator at the 689 Chan Zuckerberg Biohub and is a member of the Parker Institute for Cancer Immunotherapy 690 (PICI). G.C.H. was supported by the National Science Foundation Undergraduate Research 691 Fellowship Program 1650113. C.S.C. is further supported by NIH R35HL140026. C.H. is further 692 supported by a K23 from NHLBI K23 HL133495.

693

694 UCSF COMET Consortium co-authors: Yumiko Abe-Jones, Michael Adkisson, K. Mark Ansel, 695 Saurabh Asthana, Alexander Beagle, Sharvari Bhide, Cathy Cai, Saharai Caldera, Maria Calvo, 696 Sidney A. Carrillo, Suzanna Chak, Stephanie Christenson, Zachary Collins, Spyros Darmanis, 697 Angela Detweiler, Catherine DeVoe, Walter Eckalbar, Jeremy Giberson, Ana Gonzalez, Gracie 698 Gordon, Paula Hayakawa Serpa, Alejandra Jauregui, Chayse Jones, Serena Ke, Divya Kushnoor, 699 Tasha Lea, Deanna Lee, Aleksandra Leligdowicz, Yale Liu, Salman Mahboob, Lenka Maliskova, 700 Michael Matthay, Elizabeth McCarthy, Priscila Muñoz-Sandoval, Norma Neff, Viet Nguyen, 701 Nishita Nigam, Randy Parada, Maira Phelps, Logan Pierce, Priya Prasad, Sadeed Rashid, Gabriella 702 Reeder, Nicklaus Rodriguez, Bushra Samad, Andrew Schroeder, Cole Shaw, Alan Shen, Austin

- ⁷⁰³ Sigman, Pratik Sinha, Matthew Spitzer, Sara Sunshine, Kevin Tang, Luz Torres Altamirano,
- ⁷⁰⁴ Alexandra Tsitsiklis, Erden Tumurbaatar, Vaibhav Upadhyay, Alexander Whatley, Andrew
- ⁷⁰⁵ Willmore, Michael Wilson, Juliane Winkler, Kristine Wong, Kimberly Yee, Michelle Yu,
- ⁷⁰⁶ Mingyue Zhou, Wandi S. Zhu

708 **References**

- 1. Arunachalam PS et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in
- 710 humans. Science (1979) 2020;369(6508):1210–1220.
- 711 2. Combes AJ et al. Global absence and targeting of protective immune states in severe COVID-19. Nature
- 712 2021;591(7848):124–130.
- 713 3. Zheng H et al. Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules
- associated with severity across viruses [Internet]. *Immunity* 2021;54(4):753-768.e5.
- 4. MacDonald L et al. COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+
- 716 monocytes [Internet]. JCI Insight 2021;6(13). doi:10.1172/jci.insight.147413
- 5. Delorey TM et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets [Internet]. *Nature*
- 718 2021;595(7865):107–113.
- 719 6. Grant RA et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia [Internet]. Nature
- 720 2021;590(7847):635–641.
- 721 7. Liao M et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 [Internet]. *Nat Med*
- 722 2020;26(6):842–844.
- 8. Ren X et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas [Internet]. *Cell*2021;184(7):1895-1913.e19.
- 9. Reyes M et al. An immune-cell signature of bacterial sepsis [Internet]. Nat Med 2020;26(3):333–340.
- 10. Reyes M et al. Plasma from patients with bacterial sepsis or severe COVID-19 induces suppressive myeloid cell
- 727 production from hematopoietic progenitors in vitro. [Internet]. Sci Transl Med 2021;13(598):9599.
- 11. Schulte-Schrepping J et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. [Internet].
- 729 *Cell* 2020;182(6):1419-1440.e23.
- 730 12. Silvin A et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
- 731 [Internet]. *Cell* 2020;182(6):1401.
- 13. Rowlands M, Segal F, Hartl D. Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in
- 733 COVID-19. Front Immunol 2021;12:2435.
- 14. Shivram H et al. Tocilizumab treatment leads to early resolution of myeloid dysfunction and lymphopenia in patients
- hospitalized with COVID-19 [Internet]. *bioRxiv* 2022;2022.10.27.514096.
- 736 15. LaSalle TJ et al. Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with
- razi severity in hospitalized COVID-19 patients [Internet]. *Cell Rep Med* 2022;3(10):100779.
- 16. Stephenson E et al. Single-cell multi-omics analysis of the immune response in COVID-19 [Internet]. Nat Med
- 739 2021;27(5):904–916.
- 17. Bost P et al. Deciphering the state of immune silence in fatal COVID-19 patients [Internet]. Nat Commun
- 741 2021;12(1):1428.

- 18. Kvedaraite E et al. Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity.
- 743 [Internet]. *Proc Natl Acad Sci U S A* 2021;118(6). doi:10.1073/pnas.2018587118
- 19. Schrijver IT, Théroude C, Roger T. Myeloid-Derived Suppressor Cells in Sepsis [Internet]. Front Immunol
- 745 2019;10:327.
- 746 20. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system [Internet]. *Nature*
- 747 *Reviews Immunology 2009 9:3 2009;9(3):162–174.*
- 748 21. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell
- 749 diversity. *Nat Rev Immunol* 2021;21(8):485–498.
- 750 22. Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity [Internet].
- 751 *Immunity* 2021;54(5):875–884.
- 23. Agrati C et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
- 753 [Internet]. Cell Death Differ 2020;27:3196–3207.
- 24. Darcy CJ et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in
- rts septic shock patients [Internet]. *Crit Care* 2014;18(4):R163.
- 25. Dean MJ et al. Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of
- Arginase Producing Granulocytic Myeloid Derived Suppressor Cells. [Internet]. Front Immunol 2021;12:695972.
- 26. Falck-Jones S et al. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and
- 759 predict COVID-19 severity [Internet]. Journal of Clinical Investigation 2021;131(6). doi:10.1172/JCI144734
- 760 27. Reizine F et al. SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and
- 761 Arginine Shortage. *J Clin Immunol* 2021;41(3):515–525.
- 762 28. Sacchi A et al. Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and
- may predict fatal COVID-19 outcome [Internet]. *Cell Death Dis* 2020;11(10):921.
- 764 29. Tom J et al. Prognostic and Predictive Biomarkers in Patients with Coronavirus Disease 2019 Treated with
- 765 Tocilizumab in a Randomized Controlled Trial* [Internet]. Crit Care Med 2022;50(3):398–409.
- 30. Bunt SK et al. Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived
- 767 Suppressor Cells and Limits Tumor Progression [Internet]. *Cancer Res* 2007;67(20):10019.
- 768 31. Chen G et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 [Internet]. J Clin
- 769 Invest 2020;130(5):2620–2629.
- 770 32. Oh K et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates
- spontaneous metastasis through IL-6 trans-signaling in a murine model [Internet]. Breast Cancer Research
- 772 2013;15(5):R79.
- 33. Weber R et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. *Cell*
- 774 Immunol 2021;359:104254.

- 34. Rosas IO et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia [Internet]. N Engl J Med
- 776 2021;384(16):1503–1516.
- 35. Shankar-Hari M et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients
- Hospitalized for COVID-19: A Meta-analysis [Internet]. JAMA 2021;326(6):499–518.
- 779 36. Sarma A et al. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS
- 780 [Internet]. *Nature Communications* 2021 12:1 2021;12(1):1–10.
- 781 37. van der Wijst MGP et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients
- with COVID-19 [Internet]. Sci Transl Med 2021;13(612):eabh2624.
- 38. Su Y et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 [Internet]. *Cell*2020;183(6):1479.
- 785 39. Aschenbrenner AC et al. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19
- 786 patients [Internet]. *Genome Medicine 2021 13:1* 2021;13(1):1–25.
- 40. Hasegawa T et al. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages [Internet].
- 788 *Atherosclerosis* 2003;171(2):211–218.
- 41. Lorenz E et al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. *Respir Med*2008;102(4):567–573.
- 42. Medina E, Hartl D. Myeloid-Derived Suppressor Cells in Infection: A General Overview [Internet]. J Innate Immun
- 792 2018;10(5–6):407–413.
- 43. Eisemann T, Costa B, Peterziel H, Angel P. Podoplanin Positive Myeloid Cells Promote Glioma Development by
- 794 Immune Suppression [Internet]. *Front Oncol* 2019;9(MAR):187.
- 44. Karakasheva TA et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of
- resophageal cancer [Internet]. *Cancer Res* 2015;75(19):4074–4085.
- 45. Newman AM et al. Robust enumeration of cell subsets from tissue expression profiles [Internet]. *Nature Methods* 2015 *12:5* 2015;12(5):453–457.
- 46. Zhou R et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses [Internet]. Immunity
- 800 2020;53(4):864.
- 47. Meckiff BJ et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19
- 802 [Internet]. *Cell* 2020;183(5):1340.
- 48. Files JK et al. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection
- 804 [Internet]. J Clin Invest 2021;131(1). doi:10.1172/JCI140491
- 49. Wilk AJ et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med
- 806 2020;26(7):1070–1076.
- 50. Diao B et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
- 808 [Internet]. Front Immunol 2020;11:827.

- 51. Mathew D et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic
- 810 implications. *Science (1979)* 2020;369(6508). doi:10.1126/SCIENCE.ABC8511
- 52. Zheng M et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients [Internet]. *Cell Mol Immunol*2020;17(5):533–535.
- 813 53. Galván-Peña S et al. Profound Treg perturbations correlate with COVID-19 severity [Internet]. *Proceedings of the*
- 814 *National Academy of Sciences* 2021;118(37):e2111315118.
- 815 54. Fahey E, Doyle SL. IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis [Internet]. Front
- 816 Immunol 2019;10(JUN):1426.
- 55. Pittet J-F et al. TGF-β is a critical mediator of acute lung injury [Internet]. *Journal of Clinical Investigation*
- 818 2001;107(12):1537.
- 819 56. R Core Team. R: A language and environment for statistical computing. [Internet]. R Foundation for Statistical
- 820 Computing, Vienna, Austria. [published online ahead of print: 2020];https://www.r-project.org. cited
- 57. McCarthy D, Campbell K, Lun A, Wills Q. scater: pre-processing, quality control, normalisation and visualisation of
- 822 single-cell RNA-seq data in R [Internet]. Scater: Pre-processing, quality control, normalization and visualization of
- single-cell RNA-seq data in R 2016;069633.
- 58. Lun ATL, McCarthy DJ, Marioni JC. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with
- 825 Bioconductor [Internet]. *F1000Res* 2016;5. doi:10.12688/f1000research.9501.2
- 826 59. Lun ATL et al. EmptyDrops: Distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing
- 827 data [Internet]. *Genome Biol* 2019;20(1):1–9.
- 828 60. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital
- gene expression data [Internet]. *Bioinformatics* 2010;26(1):139–140.
- 830 61. Bueno R et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations,
- gene fusions and splicing alterations [Internet]. *Nature Genetics* 2016 48:4 2016;48(4):407–416.
- 832 62. Hao Y et al. Integrated analysis of multimodal single-cell data [Internet]. *Cell* 2021;184(13):3573-3587.e29.
- 833 63. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis [Internet]. *Genome Biol*834 2018;19(1):15.
- 64. Pau G RJ. HTSeqGenie: A NGS analysis pipeline.. *R package version* 4.22.0. 2013;
- 836 65. Bernard GR et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant
- 837 outcomes, and clinical trial coordination. [Internet]. Am J Respir Crit Care Med 1994;149(3):818–824.
- 838 66. Ranieri VM et al. Acute respiratory distress syndrome: The Berlin definition [Internet]. JAMA Journal of the
- 839 *American Medical Association* 2012;307(23):2526–2533.
- 840 67. Angelova M et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct
- tumor escape mechanisms and novel targets for immunotherapy [Internet]. *Genome Biology 2015 16:1* 2015;16(1):1–17.
- 842

⁸⁴⁴ Tables

845

⁸⁴⁶ **Table 1. Patient characteristics**

⁸⁴⁷ NA = not available. COVACTA data are for subjects with blood RNA-seq data included in this
 ⁸⁴⁸ manuscript. COVACTA ICU admission frequency is at time of baseline sampling.

849

		COVACTA		
	All	SARS-CoV-2+	SARS-CoV-2-	
n (%)	75	57 (76%)	18 (24%)	404
Age median (IQR)	54 (42, 69)	48 (42, 66)	66 (51, 76)	63 (53-70)
Sex				
Male n (%)	52 (69%)	43 (75%)	9 (50%)	284 (70%)
Female n (%)	23 (31)	14 (25%)	9 (50%)	120 (30%)
Race n (%)				
White	20 (27%)	11 (19%)	9 (50%)	233 (58%)
Black/African American	4 (5%)	3 (5%)	1 (6%)	58 (14%)
Asian	13 (17%)	9 (16%)	4 (22%)	37 (9%)
Other/Mixed/Unknown	38 (51%)	34 (60%)	4 (22%)	76 (19%)
Baseline NIH Ordinal Scale n (%)				
3 No supplemental O2	14 (19%)	12 (21%)	2 (11%)	15 (4%)
4 Supplemental O2	25 (33%)	18 (32%)	7 (39%)	109 (27%)
5 Non-invasive/high flow O2	14 (19%)	9 (16%)	5 (28%)	114 (28%)
6 Mechanical ventilation (MV)	3 (4%)	3 (5%)	0 (0%)	58 (14%)
7 MV + additional organ support	19 (25%)	15 (26%)	4 (22%)	107 (27%)
SOFA maximal median (IQR)	4 (1, 10)	4 (1, 11)	4 (1, 9)	NA
ICU admission n (%)	26 (35%)	30 (53%)	11 (61%)	234 (58%)
Mortality n (%)	10 (13%)	6 (11%)	4 (22%)	83 (20%)
ARDS AECC definition n (%)	38 (51%)	26 (46%)	12 (67%)	NA
ARDS Berlin definition n (%)	23 (31%)	18 (32%)	5 (28%)	NA
Hospitalization, days median (IQR)	8 (8, 18)	11 (3, 20)	5 (4, 7)	22 (9-28)
ICU duration, days median (IQR)	2 (0, 9)	14 (4, 26)	4 (2, 4)	14 (0-27)
Ventilator-free days median (IQR)	28 (18, 28)	28 (16, 28)	28 (26, 28)	19 (0-28)

850 851



0.0

CONID CONID*

- Figure 2. Replication of EN-RAGE severity association across sample types in both COVID-19
 and non-COVID-19 acute lung injury (COMET cohort).
- ⁸⁶⁸ A. UMAP plots with cell type annotations. Each point represents a single cell, colored by cell type.
- Each panel shows a different sample type, as indicated. PBMC: peripheral blood mononuclear
- ⁸⁷⁰ cells, WB: whole blood, ETA:endotracheal aspirates.
- ⁸⁷¹ B. UMAP plots showing EN-RAGE signature score. Each point represented a single cell colored
- ⁸⁷² by the expression signature value.
- ⁸⁷³ C. Pseudo-bulk expression profiles within myeloid cells. Each point represents the pseudo-bulk
- gene expression signature score for a cell type in a patient sample. PBMC severity: Moderate = no
- supplemental O_2 , severe = supplemental O_2 and critical = mechanical ventilation. Whole blood
- severity: Mild/Moderate = 0 days on ventilator and no more than 1 day in ICU, Severe patients
- had ≥ 1 day on ventilator. ETA: Critical=VFDS=0 (ventilation for ≥ 28 days or death), severe
- ETA=VFDS>0. Significance was tested using a t-test across the indicated groups (n.s. = p > 0.05, ** = p < 0.01, *** = p < 0.01). Sample numbers non schort: DDMC healthy, n = 11, DDMC
- ** = p < 0.01; *** = p < 0.001). Sample numbers per cohort: PBMC healthy, n = 11; PBMC ⁸⁸⁰ COVID moderate n = 4; PPMC COVID entropy n = 6; PPMC COVID entropy n = 2; PPMC
- ⁸⁸⁰ COVID- moderate, n = 4; PBMC COVID- severe, n = 6; PBMC COVID- critical, n = 3; PBMC
- ⁸⁸¹ COVID+ moderate, n = 12; PBMC COVID+ severe, n = 10; PBMC COVID+ critical, n = 14. WB
- healthy, n = 14; WB COVID- mild, n = 4; WB COVID- severe, n = 1; WB COVID+ mild, n = 8;
- ⁸⁸³ WB COVID+ severe, n = 5. ETA COVID- moderate/severe, n = 2; ETA COVID- critical, n = 1;
- ⁸⁸⁴ ETA COVID+ moderate/severe, n = 5; ETA COVID+ critical, n = 8.

885



Figure 3. EN-RAGE signature expression correlates with disease severity and immunosuppressive gene expression in myeloid cells (COMET cohort).

- A. Spearman correlations between pseudo-bulk EN-RAGE signature score in PBMC monocytes and NIII ordinal soverity score maximal NIII soverity score SOEA ergen failure score and
- and NIH ordinal severity score, maximal NIH severity score, SOFA organ failure score, and ⁸⁹¹ alarma II (and II 10 protain levels at study applyment, **P**, **PDMC** managerts EN **PACE** and
- ⁸⁹¹ plasma IL-6 and IL-10 protein levels at study enrollment. **B.** PBMC monocyte EN-RAGE gene
- score is higher in patients who develop ARDS (AECC definition) in COVID-19 patients; n=46. Medians are indicated. * t-test p<0.05. C. Longitudinal changes in EN-RAGE signature in bulk
- ⁸⁹⁴ ETA RNA-seq. Each point represents a patient sample from COVID-19 (n=16 patients, n=276
- ⁸⁹⁵ samples) and non-COVID (n=3 patients, n=6 samples) patients requiring mechanical ventilation.
 ⁸⁹⁶ Samples from the same patient are linked by detted lines. Points are colored by severity of disease
- Samples from the same patient are linked by dotted lines. Points are colored by severity of disease.
 For illustrative purposes, linear regression trend lines for signature secrets over time, grouped by
- For illustrative purposes, linear regression trend lines for signature scores over time, grouped by severity level are shown as solid lines. Slopes were significantly different using a linear mixed
- ⁸⁹⁹ model, p<0.05. MV=mechanical ventilation. **D.** Table of Spearman correlation coefficients
- between pseudo-bulk EN-RAGE signature score and genes encoding myeloid effector functions within monocute or neutrophil populations across and tracheal againstag (ETA), whole blood, and
- within monocyte or neutrophil populations across endotracheal aspirates (ETA), whole blood, and PRMCs from the COMET schort. Resitive correlations are shaded red and negative correlations
- PBMCs from the COMET cohort. Positive correlations are shaded red and negative correlations shaded blue, with increasing darkness of shading indicating two tailed p values of p<0.05, p<0.01,
- and p<0.001. E. PBMC myeloid EN-RAGE gene score correlates with plasma IL-6 and IL-10
- ⁹⁰⁵ protein; n=46. **F.** Correlation of pseudo-bulk expression signature for EN-RAGE genes compared
- ⁹⁰⁶ to pseudo-bulk expression values of IL-10 and PD-L1 in monocytes in COMET tracheal aspirate
- 907 samples. Each point represents the expression value in a cell type in a single sample; n=40. Log₂
- ⁹⁰⁸ gene expression, Spearman correlation coefficients and two tailed p values are shown.





		Lung recruitment/phenotype					T cell suppression						
Spearman rho		HLA.DRA	HLA.DRB1	CD14	CCR2	PTGER2	STAT3	ENRAGE	IL10	PDL1	IL1B	CYBB	TGFB1
ETA	n												
Monocyte	41	0.11	-0.23	0.09	0.26	0.72	0.75	0.70	0.74	0.59	0.86	0.14	0.13
Neutrophil	40	0.03	-0.16	0.58	0.00	0.35	0.63	0.74	0.53	0.59	0.78	0.21	0.54
Blood	n												
Monocyte	18	-0.01	0.19	0.62	0.53	0.52	0.79	0.67	0.57	0.31	0.34	0.60	0.37
Neutrophil	18	-0.53	-0.52	0.78	-0.21	-0.48	0.94	0.72	0.27	0.78	0.70	0.28	0.91
PBMC	n												
Monocyte	44	-0.45	-0.48	0.65	0.25	0.38	0.15	0.73	0.15	0.02	0.34	0.52	0.18

910 911

E PBMC

F ETA



⁹¹³ Figure 4. Characterization of myeloid and T cell immunosuppression phenotypes (COMET

- ⁹¹⁴ PBMC cohort).
- ⁹¹⁵ A. EN-RAGE gene set score is most highly expressed in classical monocytes (cM) in PBMC CITE-
- seq data. ncM=non-classical monocytes, progen=progenitor cells. Cells were defined by marker
- ⁹¹⁷ genes as previously described(37). B. CD14, CD16, and HLA-DR surface protein expression ⁹¹⁸ across cell lineaces in PDMC CITE and data C E. Snorman correlations between EN PACE
- ⁹¹⁸ across cell lineages in PBMC CITE-seq data. C-E. Spearman correlations between EN-RAGE
- gene set expression in classical monocytes and protein expression on C. classical monocytes, D. 920 CD4⁺T calls and E. CD8⁺ calls: n=128 complex including 11 healthy controls. EDB < 0.05 for all
- ⁹²⁰ CD4⁺ T cells and E. CD8⁺ cells; n=128 samples, including 11 healthy controls. FDR<0.05 for all
- ⁹²¹ correlations, panel of 188 proteins measured. F-L Pseudobulked surface protein expression in 128 ⁹²² PBMC samples from 60 patients over 14 days in patients grouped by clinical outcomes. Classical
- PBMC samples from 60 patients over 14 days in patients grouped by clinical outcomes. Classical
 monocyte expression of F. EN-RAGE gene signature, G. HLA-DR protein, H. PD-L1 protein.
- ⁹²⁴ CD8⁺ T cell expression of I. PD-1 and J. LAG3. CD4⁺ T cell expression of K. PD-1 and L. LAG3.
- ⁹²⁵ Blue line denotes the linear regression trend for gene expression over time. Red line denotes
- 926 expression level in healthy controls. Vent. duration = days of mechanical ventilation in survivors.
- ⁹²⁷ n=128 samples from 60 patients (429, 505 cells). Pearson correlation coefficients (r) and p values
- 928
 929
 are indicated.

930



931



⁹³³ Figure 5. ENRAGE gene set enrichment analysis of monocytes treated with IL-6 *in vitro*.

⁹³⁴ Monocytes stimulated with IL-6 for 24 hours compared with media, selected genes visualized as

⁹³⁵ a heatmap using unsupervised clustering. A. ENRAGE signature genes. B. Genes associated with

potential T cell suppressive functionality, from Supplemental Table 2. C. FGSEA analysis of EN-

 937 RAGE and MS1 signatures in IL-6 treated monocytes. Bars represent the normalized enrichment scores of how much each gene set is regulated by IL 6 treatment (BH adjusted p value for MS1 <

scores of how much each gene set is regulated by IL-6 treatment (BH adjusted p-value for MS1 < 0.01 and EN-RAGE < 0.001).

940



942 Figure 6. Severity-associated EN-RAGE gene set is associated with poor outcome and decreased 943 by IL-6 blockade in COVID-19 patients (COVACTA cohort). A. Heatmap of EN-RAGE gene set 944 associations with NIH ordinal scale severity at D1 (Severity NIH), need for new mechanical 945 ventilation in patients not ventilated on D1 (Mech Vent), 28 day mortality (Death), treatment with 946 tocilizumab or placebo at D3 or D7 relative to D1, and tocilizumab (TCZ) vs placebo at D7 relative 947 to D1. B-E. Gene set enrichment analyses (GSEA) for gene sets associated with the myeloid cell 948 states EN-RAGE, MS1(10), and MDSC(67) and T cells (CIBERSORT(45)). Normalized 949 enrichment scores are shown, with red shading for t test p<0.05 and grey for p>0.05. TCZ = 950 tocilizumab. For C and D, analyses were adjusted for baseline severity by incorporating baseline 951 ordinal score as a covariate in our model. F-G. Tocilizumab treatment normalizes (F) EN-RAGE 952 and (G) CD8⁺ T cell gene expression to healthy levels more rapidly than placebo in survivors. 953 Only patients with measurements for all three time points are included. Lines represent the mean 954 expression value for the gene set signature score across tocilizumab- or placebo-treated subjects. 955 Error bars represent the 95% confidence interval around the mean. Patients are split into those that 956 were discharged before 28, those that remained hospitalized, or subjects that died by day 28. 957 Average signature scores are shown across the first 7 days of treatment. CTRL=healthy controls,

SOC = standard of care drug therapy; significance testing was performed using t-test comparing each day to D1 by study arm * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.





966 Figure 7. IL-6 blockade reduces potential T cell suppressive factors and normalizes T cells in 967 COVID-19 patients (COVACTA cohort). A. EN-RAGE is positively correlated with IL-6-induced 968 suppressive myeloid genes (IL-10, IL-1b, PD-L1) and inversely correlated with T cell genes 969 (FASL, LKRK1, TIGIT, CD160, IFNG, IL7R, CTLA4, XCL1, HAVCR2, TBX21, PRF1, GZMB, 970 LAG3, GZMM, PDCD1, FOXP3). Spearman correlation coefficients are shown for bulk whole 971 blood gene expression. B-C. Volcano plots of reduced expression of T cell genes in A in patients 972 with greater baseline severity (requiring positive pressure ventilation) versus not (B) and increased 973 expression of T cell genes following 7 days treatment with tocilizumab (C). Dotted lines indicate 974 absolute $> 0.5 \log_2$ fold change and FDR<0.05. D. Working model.

